Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation-Reference-Cited by-同舟云学术

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

Published:2013-06-16 Issue:6 Volume:15 Page:577-589
ISSN:1618-7598
Container-title:The European Journal of Health Economics
language:en
Short-container-title:Eur J Health Econ

Author:

Ruof Jörg,Schwartz Friedrich Wilhelm,Schulenburg J.-Matthias,Dintsios Charalabos-Markos

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s10198-013-0495-y.pdf

Reference21 articles.

1. The Federal Ministry of Health: The act on the reform of the market for medicinal products (Gesetz zur Neuordnung des Arzneimittelmarktes—AMNOG). http://www.bmg.bund.de/ministerium/english-version/amnog.html (2011). Accessed 10 Aug 2012

2. The Federal Ministry of Health: Arzneimittel-Nutzenbewertungsverordnung (AM-NutzenV). Bundesgesetzblatt (German Federal Law Gazette) 1, 2324–2328 (2010)

3. G-BA: Chapter 5: assessment of the benefits of pharmaceuticals according to §35a SGB V. http://www.english.g-ba.de/downloads/17-98-3042/2011-05-18_5%20Kapitel%20VerfO%20Englisch.pdf (2012). Accessed 10 Aug 2012

4. IQWiG: General methods 4.0. https://www.iqwig.de/download/General_Methods_4-0.pdf (2011). Accessed 29 Jun 2012

5. EMA: European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 (2012). Accessed 20 Aug 2012

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices;Applied Health Economics and Health Policy;2023-09-26

2. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit;Health Economics, Policy and Law;2023-08-14

3. Health Technology Assessment–Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact;Value in Health;2023-07

4. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries;BMC Health Services Research;2023-02-13

5. Do France, Germany, and Italy agree on the added therapeutic value of medicines?;International Journal of Technology Assessment in Health Care;2023